Minutes - TRIPS Council - View details of the intervention/statement

H.E. Ambassador Xolelwa Mlumbi-Peter (South Africa)
15 PROPOSAL FOR A WAIVER FROM CERTAIN PROVISIONS OF THE TRIPS AGREEMENT FOR THE PREVENTION, CONTAINMENT AND TREATMENT OF COVID-19

1050.   The COVID-19 Pandemic poses an enormous challenge to the global community. The urgent need for a new vaccine and effective medical products to combat the novel coronavirus is out of question. 1051.   Switzerland fully acknowledges the challenges that come with the current pandemic. In these trying times, it is imperative for WTO Members and all stakeholders, whether public or private, nongovernmental, scientists and researchers, to collaborate in close partnership to ensure rapid, affordable and equitable access to medical products. So how can we best ensure access at a global scale? 1052.   Under the heading of COVID-19, the authors of document IP/C/W/669 propose a sweeping waiver from the implementation, application and enforcement of most of the intellectual property protection that the TRIPS Agreement provides for. 1053.   Switzerland shares the concern that individual Members and the international community must now do everything that is necessary to ensure affordable and equitable access to COVIDrelated medical products globally. However, Switzerland does not believe that a TRIPS waiver is the right way forward to achieve this goal. On the contrary, we are convinced that such a move would have the opposite effects from those looked for. 1054.   The intellectual property system has been and continues to be a pivotal factor ensuring a pipeline of innovative pharmaceutical products, including vaccines to work. It is the reliable legal framework which provides the foundation for stakeholders, for the public and private actors, to invest, work and innovate together. IP rights, and in particular patents, spur stakeholders' interaction, and enable them to share information, knowledge and data, to aliment the global databases, license in and out technology, and to do what is necessary to eventually scale up capacity. 1055.   Declaring a TRIPS waiver for COVID-19 would mean to put into question the foundation of a large part of the investments and efforts currently undertaken to research and develop a vaccine and medical products against the novel coronavirus. It would risk undermining the partnerships that bring about first results in the fight against the global pandemic. Rather, we need to ensure that the unprecedented collaboration between all relevant actors, who have come together over the past few months to do everything possible to contain the crisis, continues without disruption. 1056.   This being said, as soon as Research & Development for a new vaccine and medicines against the novel coronavirus will succeed, equitable and affordable access to these innovative products must be ensured. To meet this challenge, all relevant factors need to be taken into account that determine access. It is important that we continue to address the challenges ahead in a holistic and sustainable manner, and within the rules-based multilateral trading system. 1057.   The TRIPS Agreement, strikes the right balance, provides for the necessary means and remedies to allow the use of protected content and products, should voluntary mechanisms fail. In such an instance, a country may make use of the flexibilities which WTO Members confirmed in the Doha Declaration on TRIPS and public health. 1058.   We should avoid sweeping measures resulting in a comprehensive revocation of rights for the time of the pandemic which would disincentivize efforts underway. Rather, the collaborations and partnerships currently engaged in the search of a new vaccine and medicines against the virus must be deployed to work for broad and equitable access. 1059.   We need to continue working at the multilateral level and supporting global initiatives. Several mechanisms, which facilitate access to medicines and other health technologies to fight diseases other than COVID-19 for the poorest countries, already exist. These are voluntary collaborations between the private and public sectors and international initiatives. For COVID-19, we should build on the ample experience that is already there. 1060.   Among the many initiatives under way, I would like to highlight the COVID-19 Vaccine Global Access facility (COVAX) and the Gavi COVAX Advance Market Commitment (AMC). These and others take IP as an important basis for the cooperation of the participating stakeholders and their joint endeavour. 1061.   Switzerland has released CHF 400 million in support of international action in response to COVID-19. Working together with partners and the relevant international organizations to find global solutions for access and an equitable distribution of COVID-19 medical products for all countries, Switzerland supports all three pillars of the Access to COVID-19 Tools (ACT) Accelerator. This to ensure global collaboration to accelerate and scale up development, production and equitable access to diagnostics, treatments as well as a future COVID-19 vaccine. 1062.   Switzerland further supports international partnership organizations such as Coalition for Epidemic Preparedness Innovations (CEPI) or the vaccines alliance GAVI. They have a leading role together with the ACT Accelerator in the process, covering the four pillars of access in the response to the pandemic. As part of the holistic response to the challenges we face, we also welcome the recent initiatives aiming at facilitating international trade in essential goods in order to promote more resilient and diversified supply chains. 1063.   To sum up, partnerships, multilateralism, a sound and reliable legal framework and IP protection as provided by the TRIPS Agreement are essential for the collaboration that we see now engage in the process of innovative research and development for a vaccine and effective treatments against the novel coronavirus. Switzerland calls on Members to engage in and contribute to those international initiatives and partnerships, which in that collaborative spirit prepare and work towards ensuring equitable access. 1064.   Let's hope for the best, that we will soon have such a new vaccine and safe, medical products at our disposal against the novel coronavirus, to fight the pandemic effectively together.

The Council so agreed.
84. The Chair said that this item had been put on the agenda at the request of India and South Africa; and a communication had been circulated. She invited India and South Africa to introduce their proposal.
85. The representatives of India and South Africa took the floor.
86. The Chair invited Members to take the floor.
87. The representatives of Kenya; Nigeria; Bangladesh; Sri Lanka; Pakistan; the Bolivarian Republic of Venezuela; Nepal; Philippines; Nicaragua; Chile; Turkey; Egypt; Indonesia; Argentina; Chad, on behalf of the LDC Group; China; Thailand; Tunisia; Tanzania, on behalf of the African Group; Ecuador; Senegal; Costa Rica; Mauritius; Colombia; El Salvador; Mali; Jamaica; the European Union; the United States of America; Switzerland; Japan; Norway; the United Kingdom; Brazil; Mozambique; Canada; Australia; Honduras; the Holy See; the World Health Organization (WHO) and the United Nations Programme on HIV/AIDS (UNAIDS) took the floor.
88. The Chair invited the Secretariat to share procedural requirements.
89. The representative of the Secretariat took the floor.
90. The representative of the United States of America took the floor.
91. The Chair noted that the proposal had been submitted to the Council on 2 October 2020. Thus, the 90-day time-period would expire on 31 December 2020. For practical purposes, this would mean that the last opportunity for the Council to adopt the report envisaged by Article IX:3 (b) of the Marrakech Agreement, was before the end-year-break in December. In order to facilitate reconvening the Council to consider a report in this regard, she proposed to keep the agenda item open. She encouraged Members to further consult on the proposal and explore possibilities to bridge the gap.
92. The Council took note of the statements made and agreed to keep the agenda item open.
93. At the Council for TRIPS' reconvened formal meeting of 10 December 2020, the Chair reported that, on 20 November and on 3 December, she had convened the Council in informal open-ended mode to take stock of developments since the suspension in October, and to continue the consideration of the agenda item in informal mode. At these meetings delegations had highlighted their common goal of providing access to high-quality, safe, efficacious and affordable vaccines and medicines for all. Delegations had also exchanged views, sought clarifications and provided information on the operation, implementation and impact of the requested waiver during these meetings.
94. The Chair said she also held consultations in the time-period between 26 November and 1 December, in order to seek delegations' views on (a) what kind of report the TRIPS Council could likely agree on at today's meeting, and (b) how substantive engagement could be further facilitated, given the importance of meaningful and focused discussions on the substance of the proposal. In these consultations she had detected an emerging agreement that the TRIPS Council should provide a communication to the General Council that would be neutral and factual, and reflect the state of play of discussions and the absence of consensus on the waiver proposal in the TRIPS Council at this time. Delegations had also seen a need to continue discussions on the matter within the TRIPS Council.
95. On the basis of these consultations, and after discussions in the informal open-ended meeting on 3 December, an agenda item for a status report on the consideration of the waiver request was put on the proposed agenda of the next General Council meeting scheduled for 1617 December. During the informal meeting of 3 December, the Chair had circulated draft language for such an oral status report with an invitation to Members to comment on this language by 7 December. On the basis of the comments that were received by the deadline, she had held further consultations on 8 and 9 December, and had circulated a revised draft status report.
96. In light of these informal meetings and consultations, she proposed the Council agree that she would deliver an oral status report to the General Council as follows:
At the meeting of the TRIPS Council on 15-16 October 2020, India and South Africa introduced document IP/C/W/669, requesting a waiver from certain provisions of the TRIPS Agreement for the prevention, containment and treatment of COVID-19, which had been circulated on 2 October 2020 and has since been co-sponsored by the delegations of Kenya, Eswatini, Pakistan, Mozambique, and Bolivia. The Council continued its discussions under that agenda item at its resumed meeting on 10 December 2020.
At those meetings, and at informal meetings on 20 November and 3 December, delegations highlighted the common goal of providing access to high-quality, safe, efficacious and affordable vaccines and medicines for all. Delegations exchanged views, sought clarifications and provided information on the waiver request but could not reach consensus. Delegations indicated a need for further discussions on the waiver request and views exchanged by delegations.
This means that the TRIPS Council has not yet completed its consideration of the waiver request and may not be able to do so within the 90 days stipulated in Article IX:3 of the Marrakesh Agreement. Therefore, the TRIPS Council will continue its consideration of the waiver request and report back to the General Council as stipulated in Article IX:3 of the Marrakesh Agreement.
97. The Council so agreed.
98. The Chair thanked all delegations, particularly those involved in the consultations, for the constructive spirit in which they had engaged in the discussions on this report. As regards the TRIPS Council's next steps, she noted that the next regular meeting is scheduled for 1011 March 2021. In order to allow for further consideration of the waiver request in the more immediate future, she proposed that the Council reserve 19 January and 4 February 2021 for meetings of the Council that could be dedicated to the discussion of the waiver request. The next regular meeting – with the usual complete agenda – would remain scheduled for 10-11 March.
99. The Council so agreed.
100. The representatives of Malaysia, Canada, Chile, Bolivia, Sri Lanka, Chad, Norway, Turkey, Singapore, Viet Nam, Eswatini, Egypt, Indonesia, the European Union, Japan, China, the United Kingdom, Oman, Mauritius, Bolivarian Republic of Venezuela, Ukraine, the United States of America, Ecuador, the Republic of Korea, El Salvador, New Zealand, Mozambique, Brazil, Jamaica, India, Pakistan, Switzerland, Israel, Colombia, Bangladesh, Tanzania, on behalf of the African Group, Botswana, South Africa, Nepal and Vanuatu took the floor.
IP/C/M/96, IP/C/M/96/Add.1